Adagio's new crown antibody phase II/III study was successful!

Article source: Medical Cube Info

Author: Pickup

On March 30, Adagio announced that the company's investigational COVID-19 neutralizing antibody ADG20 is in ongoing global Phase II/III clinical trials as a pre- and post-exposure prophylaxis (EVADE) and therapeutic (STAMP) drug for COVID-19 , the primary endpoint was statistically significant across all 3 indications

In the primary efficacy analysis of the pre-exposure prophylaxis (PrEP) cohort in the EVADE study, adintrevima reduced the relative risk by 71% over the 3-month period compared to the placebo group by month 3 or at the onset of Omicron

Following the advent of Omicron (BA.

In the primary efficacy analysis of the post-exposure prophylaxis (PEP) cohort in the EVADE study, adintrevimab reduced 28-day relative risk by 75% compared with placebo

In the STAMP study of patients with mild to moderate COVID-19 infection at high risk of disease progression, adintrevimab reduced the risk of hospitalization or all-cause death by 66% by day 29

The safety profile of a single intramuscular (IM) injection of 300 mg adintrevimab was similar to placebo in both trials

Since the emergence of Omicron, the use of neutralizing antibodies against COVID-19 from many companies has been restricted by the FDA

On January 24 this year, Regeneron's cocktail therapy REGN-COV2 and Eli Lilly's cocktail therapy bamlanivimab and etesevimab were also restricted by the FDA because they were unlikely to be effective against omicron mutants

However, Eli Lilly's third neutralizing antibody, bebtelovimab, was approved by the FDA on February 11 this year because it was effective against Omicron